-
Atopic dermatitis patients to be denied NHS access to Dupixent
pharmatimes
July 19, 2018
The National Institute for Health and Care Excellence has issued draft guidance rejecting Sanofi/Regeneron’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis.
-
Vertex mulls over NHS England’s offer for CF drugs
pharmatimes
July 19, 2018
Vertex Pharmaceuticals is considering a final offer from NHS England on funding for its cystic fibrosis therapies, but said it remains concerned that the deal on the table does not fully reflect the value of its existing and future medicines for the condi
-
NICE calls for quicker treatment of kidney stone patients in pain
pharmatimes
July 19, 2018
The National Institute for Health and Care Excellence has released new draft guidelines calling for faster treatment of patients with kidney stones experiencing severe pain.
-
NICE ‘no’ for Roche’s Ocrevus
pharmatimes
July 18, 2018
The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s multiple sclerosis therapy Ocrevus.
-
NICE calls to limit antibiotic use in COPD over antimicrobial resistance fears
pharmafile
July 17, 2018
NICE have published a draft antimicrobial prescribing guide recommending that healthcare professionals should consider the risk of antimicrobial resistance when deciding whether to prescribe antibiotics in treating chronic obstructive pulmonary disease (C
-
NICE approves treatment for rare and deadly childhood cancer
pharmafile
July 17, 2018
NICE has recommended that monoclonal antibody dinutuximab beta be used in treating high-risk neuroblastoma – a rare and deadly form of cancer that mainly affects young children.
-
NICE backs AZ’ asthma biologic Fasenra
pharmatimes
July 17, 2018
AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.
-
NICE advises restricted use of antibiotics for COPD
pharmatimes
July 16, 2018
The National Institute for Health and Care Excellence is advising healthcare professionals to restrict use of antibiotics for chronic obstructive pulmonary disease (COPD).
-
NICE backs use of dye for brain tumour removal
pharmatimes
July 16, 2018
NICE has published new guidelines recommending use of a chemical dye to assist neurosurgeons in removing brain tumours.
-
NICE turns down Darzalex combo for pre-treated multiple myeloma
pharmatimes
July 16, 2018
According to Janssen, the decision comes despite the consultation papers highlighting the regimen as an innovative treatment combination, which the firm said boosts overall survival and slashes the risk of death by 50 percent.